. 2020 Nov 11;11:572373. doi: 10.3389/fphar.2020.572373

TABLE 7.

Anti-cancer effect of Sal B.

Animal models/cell types	Stimuli	Concentration of Sal B	Mechanisms	References
*In vivo*
Breast cancer (nude mouse)	MDA-MB-231 cells	80 mg/kg (i.p.) (three times per week)	PCNA, Bcl-xL, survivin↓	(Sha et al., 2018)
Colorectal cancer (nude mouse)	HCT116 cells	80 mg/kg (i.p.)	LC3-II↑	(Jing et al., 2016)
Colorectal cancer (nude mouse)	HCT116 cells	80 mg/kg (i.p.)	AKT/mTOR signaling pathway↓	(Jing et al., 2016)
HNSCC (Nude mouse)	JHU-013 cells	40, 80 mg/kg (i.p.)	PCNA, COX-2↓	(Zhao et al., 2010)
Cardiotoxicity (mouse)	ATO	2 mg/kg (tail vein injection)	CK, LDH, GOT, CAT, Bax↓	(Wang et al., 2013b)
Cardiotoxicity (mouse)	ATO	2 mg/kg (tail vein injection)	SOD, GSH-PX, Bcl-2, p-Akt↑	(Wang et al., 2013b)
Squamous cell carcinoma (hamster)	DMBA	10 mg/kg (i.g.)	Glutaminolysis, glycolysis, inflammation, tumor angiogenesis↓	(Wei et al., 2012)
Squamous cell carcinoma (hamster)	DMBA	10 mg/kg (i.g.)	Cholesterol and myo-inositol metabolism↑	(Wei et al., 2012)
*In vitro*
Osteosarcoma cell line MG63	—	1, 10, 50, 100 µM	Cleaved Caspase-3, p-p38, p-p53, ROS↑	(Zeng et al., 2018)
Human breast cancer cell lines MCF-7 and MDA-MB-231	—	50, 100, 150, 200 μM	Cyclin B1, Bcl-xL, survivin, GCS, GM3 enzymes↓	(Sha et al., 2018)
Human breast cancer cell lines MCF-7 and MDA-MB-231	—	50, 100, 150, 200 μM	ceramide↑	(Sha et al., 2018)
Human colon cancer cell lines HCT116 and HT29	BafA1	25, 50, 100, 200,400 μM	LC3-II/I ratio, cleaved PARP, cleaved-Caspase-9, cleaved-Caspase-3↑	(Jing et al., 2016)
Human colon cancer cell lines HCT116 and HT29	BafA1	25, 50, 100, 200,400 μM	AKT/mTOR signaling pathway↓	(Jing et al., 2016)
Hepatocellular carcinoma cell lines SK-Hep-1 and Bel-7404	—	100, 200 μM	Cleaved PARP, cleaved Caspase-3, cleaved Caspase-9, cytochrome c, LC-3, p62, Beclin-1↑	(Gong et al., 2016)
			p-AKT, p-mTOR, p-4EBP1, p-P70S6K↓
			AKT/mTOR signaling pathway↓
HNSCC Cell lines JHU-013, and JHU-022	-—	50, 100 μM	COX-2, PGE2, Bcl-2, EGFR↓	(Zhao et al., 2010)
HNSCC Cell lines JHU-013, and JHU-022	-—	50, 100 μM	p53↑	(Zhao et al., 2010)
HepG2, HeLa cells	ATO	10 μM	Procaspase-3↓	(Wang et al., 2013b)
HepG2, HeLa cells	ATO	10 μM	Cleaved PARP↑	(Wang et al., 2013b)
Human glioma U87 and U373 cells	Radiation, temozolomide	0.5 μM	`²⁺ buffering capacity↓	(Chen W. et al., 2018)
Human glioma U87 and U373 cells	Radiation, temozolomide	0.5 μM	Fis-1↑	(Chen W. et al., 2018)
OSCC Cell lines CAL27 and SCC4	—	50, 100, 200 μg/ml	CAL27	(Yang et al., 2011)
			Tenascin C, Osteoponti, HIF-1α, TGFb1, COX-2, HGF, Scya2, IL-10, TGFbR2, Mmp2↓
			THBS2↑
			SCC4
			HIF-1α, Mmp9, TGF b3, VEGF, VEGF-C, TNFa↓
			THBS2, Timp1↑
Human GC cell line BGC-823	—	200 μM	citH3, MPO↓	(Tao et al., 2018)

DMBA, 7,12-dimethylbenz(a)anthracene; BafA1, bafilomycin A1; HNSCC, head and neck squamous cell carcinoma; OSCC, oral squamous cell carcinoma; i.p., intraperitoneally; i.g., intragastrically.